摘要
目的分析银屑病住院患者的用药和经济负担,为促进合理用药及优化卫生资源配置提供参考依据。方法整群抽取中南大学湘雅二医院住院病案系统,收集整理2012—2022年临床诊断包含银屑病的住院患者信息,进行用药和经济负担分析。结果共纳入3121例患者,以男性、30~60岁、湖南患者居多。糖皮质激素、抗组胺药物、维生素D_(3)类似物是较常用的药品,单抗类生物制剂的药品单价最贵。患者人均住院总费用为(10216.97±7303.53)元,人均西药费为(5998.60±5913.94)元。银屑病患者住院总费用的主要影响因素依次为西药费、住院时长、是否有并发症、银屑病临床分型以及是否使用生物制剂。结论银屑病患者的医疗费用主要花费在药物方面,因此通过制定合理和个性化的药物治疗方案等措施可以在一定程度上减轻银屑病患者的经济负担。
Objective To analyze the drug use and economic burden of inpatients with psoriasis and to provide a basis for rational use of medicines and optimal allocation of health resources.Methods The inpatient medical record system of the Second Xiangya Hospital of Central South University was selected from the whole group,and the information of inpatients with psoriasis from 2012 to 2022 was collected and analyzed for medication use and economic burden.Results A total of 3 121 patients were included,most of which were males,patients aged 30~60 years,people from Hunan Province.Glucocorticoids,antihistamines and vitamin D_(3) analogues were the most commonly used drugs,and monoantibody biological agents was the most expensive drug.The total hospitalization cost per capita was(10 216.97±7 303.53) yuan,and the average western medicine cost per capita was(5 998.60±5 913.94) yuan.The main influencing factors of total hospitalization cost of psoriasis inpatients were western medicine cost,length of stay,whether there were complications,clinical classification of psoriasis and whether biological agents were used in turn.Conclusion The costs of psoriasis inpatients were mainly spent on drugs,so through reasonable and personalized drug program and other measures can reduce the economic burden of patients with psoriasis to a certain extent.
作者
万小敏
刘金艳
刘俏
易利丹
罗霞
WAN Xiao-Min;LIU Jin-Yan;LIU Qiao;YI Li-Dan;LUO Xia(Department of Pharmacy,the Second Xiangya Hospital of Central South University,Changsha 410011,China;Institute of Clinical Pharmacy,Central South University,Changsha 410011,China;Department of Forensic Medicine,School of Basic Medicine,Central South University,Changsha 410000,China)
出处
《中国药物经济学》
2024年第1期20-26,共7页
China Journal of Pharmaceutical Economics
基金
湖南省自然科学基金(2021JJ40817、2022JJ80040、2023JJ60503)
湖南省卫健委科研项目(202113050611、202113050283、202213053462)。
关键词
银屑病
合理用药
经济负担
Psoriasis
Rationaluseofmedicines
Economicburden
